TLR7 agonists can be used as vaccine adjuvants or to boost anti‐tumour immunity, while antagonists may be beneficial in conditions such as systemic‐lupus erythematosus or rheumatoid arthritis, where TLR7 mediates the production of type I IFN. The gene discussed is TLR7; the disease is rheumatoid arthritis.